Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk

Medical Oncology

Volumn 31, Issue 10, 2014, Pages 1-5

  Karakaxas, Dimitrios ^a   Gazouli, Maria ^b   Coker, Ahmet ^c   Agalianos, Christos ^a   Papanikolaou, Ioannis S ^d   Patapis, Pavlos ^d   Liakakos, Theodoros ^d   Dervenis, Christos ^a  

^a AGIA OLGA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c EGE UNIVERSITY   (Turkey)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

IPMN; Pancreatic cancer; PDAC; pNET; TNF

Indexed keywords

DNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOTYPE; GERMLINE MUTATION; GREECE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; POPULATION BASED CASE CONTROL STUDY; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CLASSIFICATION; TUMOR VOLUME; TURKEY (REPUBLIC); CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; NEUROENDOCRINE TUMOR; PANCREAS CARCINOMA; PANCREAS TUMOR; PAPILLARY CARCINOMA; PROCEDURES;

CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919922595     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0241-z     Document Type: Article

References (21)

1. Krampitz GW, Norton JA. Pancreatic neuroendocrine tumors. Curr Probl Surg. 2013;50:509–45.
2. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8:54–64.
3. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol. 2002;14:38–45.
4. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.
5. Grötzinger C. Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):8–11.
6. Öberg K. Carcinoid tumors-current considerations. In: Modlin IM, Oberg K, editors. A century of advances in neuroendocrine tumor biology and treatment. Felsenstein C.C.C.P; 2007. p. 40–53.
7. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fléjou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32:133–8.
8. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41.
9. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest. 1998;28:1038–49.
10. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314–20.
11. Berković M, Cacev T, Zjacić-Rotkvić V, Kapitanović S. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2006;84:346–52.
12. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev. 2006;15:726–31.
13. Wu GY, Lu Q, Hasenberg T, Niedergethmann M, Post S, Sturm JW, Keese M. Association between EGF, TGF-{beta}1, TNF-{alpha} gene polymorphisms and cancer of the pancreatic head. Anticancer Res. 2010;30:5257–61.
14. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood. 2001;97:3707–12.
15. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
16. Puetzal L, Lewis CE, Lorenzen J, McGee OD. Growth factors: regulation of normal and neoplastic growth. J Pathol. 1993;169:191–201.
17. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011;61:113–32.
18. Barber MD, Powell JJ, Lynch SF, Gough NJ, Fearon KC, Ross JA. Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin Exp Immunol. 1999;117:425–9.
19. Wieser F, Fabjani G, Tempfer C, Schneeberger C, Zeillinger R, Huber JC, Wenzl R. Tumor necrosis factor-alpha promotor polymorphisms and endometriosis. J Soc Gynecol Investig. 2002;9:313–8.
20. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D’Alfonso S. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3–19.
21. Kimura W, Makuuchi M, Kuroda A. Characteristics and treatment of mucin-producing tumor of the pancreas. Hepatogastroenterology. 1998;45:2001–8.